Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 14/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753479 | 0.89 | MCHR1 (0.57) | TSHRCYP3A4MCHR1KCNH2 | |
| SCHEMBL1753859 | 0.88 | MCHR1 (0.51) | TSHRUSP2ALDH1A1TP53CYP1A2 | |
| SCHEMBL1753499 | 0.82 | MCHR1 (0.55) | CYP3A4MCHR1KCNH2 | |
| SCHEMBL1753890 | 0.81 | MCHR1 (0.56) | MCHR1KCNH2 | |
| SCHEMBL14161241 | 0.78 | MCHR1 (0.62) | CYP3A4MCHR1KCNH2 | |
| SCHEMBL1753728 | 0.77 | MCHR1 (0.54) | CYP3A4MCHR1KCNH2 | |
| SCHEMBL1753817 | 0.77 | MCHR1 (0.54) | CYP3A4MCHR1KCNH2 | |
| SCHEMBL1753724 | 0.77 | TSHR (0.44) | TSHRUSP2ALDH1A1TP53CYP1A2 | |
| SCHEMBL1753857 | 0.76 | MCHR1 (0.52) | CYP3A4MCHR1KCNH2 | |
| SCHEMBL1753489 | 0.76 | TSHR (0.55) | TSHRUSP2ALDH1A1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102208-B1 | NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-23 | — | — | EP | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| WO-2008068265-A1 | NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | MCHR1, MCHR2, MC1R | TSHR 388/4885USP2 4764/4885ALDH1A1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.